D. Lynn Kirkpatrick - Concepedia

Author

D. Lynn Kirkpatrick

University of Arizona

Also Known As

Anne Birmingham, D L Kirkpatrick, D Lynn Kirkpatrick, D. Lynn Kirkpatrick, D. Lynn Kirkpatrick, PhD, D.Lynn Kirkpatrick

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

University of Arizona University of Regina The University of Texas MD Anderson Cancer Center University of Pittsburgh UPMC Hillman Cancer Center

About

D. Lynn Kirkpatrick is an author at University of Arizona specializing in medicine, pharmacology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	822
2	Biochemistry	5	5	348
3	Natural Sciences	3	3	244
4	Engineering	2	2	92
5	Health Sciences	1	1	50

D. Lynn Kirkpatrick

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α Mei Yee Koh, Taly R. Spivak-Kroizman, Sara Venturini, Molecular Cancer Therapeutics	2008	295
Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance Nathan T. Ihle, Robert Lemos, Peter Wipf, Cancer Research	2008	273
The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Sarah J. Welsh, Ryan Williams, Anne Birmingham, PubMed PathologyRedox BiologyRedox ProteinTumor BiologyOxidative Stress	2003	252
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts Nathan T. Ihle, Gillian Paine-Murrieta, Margareta Berggren, Molecular Cancer Therapeutics	2005	150
Mechanisms of Inhibition of the Thioredoxin Growth Factor System by Antitumor 2-Imidazolyl Disulfides D. Lynn Kirkpatrick, Miles Kuperus, Marla Dowdeswell, Biochemical Pharmacology Medicinal ChemistryBiochemistryAntiparasitic AgentMedicineNatural Sciences	1998	138
A Phase I Pharmacokinetic and Pharmacodynamic Study of PX-12, a Novel Inhibitor of Thioredoxin-1, in Patients with Advanced Solid Tumors Ramesh K. Ramanathan, D. Lynn Kirkpatrick, Chandra P. Belani, Clinical Cancer Research	2007	102
The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma Amanda F. Baker, Tomislav Dragovich, Wendy R. Tate, Journal of Laboratory and Clinical Medicine 1-Methylpropyl 2-Imidazolyl DisulfideMedicinePharmacologyPathologyVegf Levels	2006	90
Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor Emmanuelle J. Meuillet, Zuohe Song, Robert Lemos, Molecular Cancer Therapeutics	2010	72
Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys73 → Ser mutation John R. Gasdaska, D. Lynn Kirkpatrick, W.R. Montfort, Biochemical Pharmacology Reductive StressBiochemistryRedox RegulatorMedicineNatural Sciences	1996	71
Selenium and the thioredoxin redox system: effects on cell growth and death. Garth Powis, John R. Gasdaska, Pamela Y. Gasdaska, PubMed Cell DeathCell GrowthRedox BiologyRedox ProteinTumor Biology	1997	70

Page 1